Search
Ascendis Pharma A/S
ASNDAdd to Watchlist
251.270USD
-1.730-0.68%
Close 10-30 16:00（ET）
15.20BMarket Cap
36.19P/E TTM
Ascendis Pharma A/S (ASND) Stock Price Target & Forecast
Analyst Rating
Based on 23 analysts giving stock ratings to Ascendis Pharma A/S in the past month.
Buy
9 Strong Buy
13 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
309.622USD+24.07%
ASND Analyst Recommendation Trends
In the current month, ASND has received 13 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the last month is 309.622.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
9
9
10
10
10
9
9
9
13
13
10
10
10
9
9
9
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
22
20
20
20
18
18
18
ASND Analyst Rating for Peer Comparison
Updated: Oct 29, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, ASND EPS is projected to reach 1.069 in FY2026Q3, following reported EPS of 3.678 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.05
0.23
1.54
1.07
1.43
Actual
-0.64
11.79
3.68
--
--
Surprise
-1183.66%
+5096.39%
+138.81%
--
--
FAQs
What is Ascendis Pharma A/S's expected revenue for the next quarter?
Ascendis Pharma A/S's expected revenue is 409.81M.
What is Ascendis Pharma A/S's price target?
Analysts forecast that Ascendis Pharma A/S's price target is USD 309.62, with the highest forecast at USD 344.00 and the lowest forecast at USD 268.00.
How have Ascendis Pharma A/SASND's recent earnings per share performed?
The market expectation was USD 3.68, while Ascendis Pharma A/SASND's earnings per share (EPS) for the previous quarter was USD 11.79. EPS for the next quarter is expected at USD 1.07.
What is the analyst rating for Ascendis Pharma A/S?
Based on the ratings of Ascendis Pharma A/S's stock from 23 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.